Skip to main content

In vitro susceptibility of Staphylococcus aureus towards amoxycillin-clavulanic acid, penicillin-clavulanic acid, dicloxacillin and cefuroxime

Buy Article:

$51.00 plus tax (Refund Policy)

Abstract:

Skov R, Frimodt-Møller N, Espersen F. In vitro antimicrobial susceptibility of Staphylococcus aureus to amoxycillin-clavulanic acid, penicillin-clavulanic acid, dicloxacillin and cefuroxime. APMIS 2002;110:559–64.

Sixty-three Staphylococcus aureus isolates with a wide distribution in quantitative β-lactamase production were tested in vitro against amoxycillin and penicillin in combination with clavulanic acid to establish the influence of total amount of β-lactamase present on the ability of clavulanic acid to protect against β-lactamase degradation. The β-lactamase stability of cefuroxime and dicloxacillin was also evaluated. MIC was determined by agar dilution using Mueller-Hinton agar with both a conventional as well as a 100 times higher inoculum. The strains were tested both with and without induction of the β-lactamase production. Clavulanic acid was highly effective in protecting against β-lactamase degradation of both penicillin and amoxycillin. Even when using a high inoculum of strains with induced β-lactamase production, all strains had MICs below the NCCLS breakpoint of 4/2 mg/l for amoxycillin-clavulanic acid. Both cefuroxime and dicloxacillin were highly stable against staphylococcal β-lactamase degradation. This study encourages further in vivo evaluation of amoxycillin-clavulanic acid for severe staphylococcal infections.

Keywords: Staphylococcus aureus; amoxycillin; clavulanic acid; susceptibility testing

Document Type: Research Article

DOI: https://doi.org/10.1034/j.1600-0463.2002.11007807.x

Affiliations: Department of Research and Development, Statens Serum Institut, Copenhagen, Denmark

Publication date: 2002-08-01

  • Access Key
  • Free ContentFree content
  • Partial Free ContentPartial Free content
  • New ContentNew content
  • Open Access ContentOpen access content
  • Partial Open Access ContentPartial Open access content
  • Subscribed ContentSubscribed content
  • Partial Subscribed ContentPartial Subscribed content
  • Free Trial ContentFree trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more